Initiate a Phase 1b/2 trial in EBV-positive solid tumors
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 24 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- October 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“and a Phase 1b/2 trial in EBV-positive solid tumors in 2021”
What we found
Evidence strength A What the grades mean
Later 10-K filings state the company initiated a multinational Phase 1b/2 trial in EBV+ solid tumors in October 2021, before the 2021 deadline. Filings are under the Viracta name.
-
A Sunesis Pharmaceuticals Inc. 10-K filed 2022-03-17
“In October 2021, Viracta initiated a multinational Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma” ✓ confirmed on the page
-
A Sunesis Pharmaceuticals Inc. 10-Q filed 2022-11-10
“increased costs to support the advancement of our Phase 1b/2 trial for the treatment of EBV+ solid tumors, which was initiated in the fourth quarter of 2021” ✓ confirmed on the page
-
A Sunesis Pharmaceuticals Inc. 10-K filed 2023-03-14
“In October 2021, Viracta initiated a multinational Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 1b/2 trial in EBV-positive solid tumors
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Sunesis Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C061027-024324 · Corrections policy